Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N201810016 A Phase III, Double-blind, Placebo controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N201903127 A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N201905120 A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA2) Lung Cancer SHH Pulmonary Medicine

Po-Hao Feng

 02-6620-2589
N201912030 A Phase 3, Randomized, Doubleblind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemothera py plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab o r Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202004125 A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202005083 A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202005083 A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202009060 A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib (The SAVANNAH Study) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202009060 A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib (The SAVANNAH Study) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202010052 A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
1 2 3 4 5 6 / 6

TOP